APMD Stock Forecast: Apnimed, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$16
−6.72% on the day

The median 12-month analyst price target for Apnimed, Inc. is $50. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 4 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$669.8M
Ticker Nerd rank
4/ 100
Median analyst target
$50
Analysts covering
4
Revenue$12.1M−29.4% y/y
Operating income−$11.7M
Net income$125.9M
Free cash flow−$18.4M
Quarterly, 4 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.9%
1M
−13.1%
From high
−50.6%
From low
+13.6%
$14
$33
Range since 31 July 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Apnimed, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
4/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
57
Value
28
Momentum
11
Growth
10
Quality
5
Accruals
5
Volatility
4
Issuance
4

Revisions (57): Analysts have, on balance, been raising their forecasts.

Issuance (4): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

APMD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on APMD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 31 July 2026Adjusted close, US dollars
$10$20$30$40$50$60Aug 26Sep 26Oct 26Nov 26APMDHigh $60Median $50Low $40

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4
Buy
0
Hold
0
Sell
$40
Low
$50
Median
$60
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
25 Aug 2026B of A SecuritiesInitiatesBuy$41
25 Aug 2026Cantor FitzgeraldInitiatesOverweight$60
25 Aug 2026Evercore ISI GroupInitiatesOutperform—
25 Aug 2026LifeSci CapitalInitiatesOutperform$50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for APMD.

Market Radar

This page is one stock. Monday covers all of them.

APMD appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

APMD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

APMD vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140Aug 26Sep 26Oct 26Nov 26APMDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

APMD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
1.2×

Cheaper than 92% of US stocks

Price / sales
6.2×

Cheaper than 18% of US stocks

Price / book
—
EV / EBITDA
29.7×

Cheaper than 11% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
90.0%

Higher than 96% of US stocks

Operating margin
11.4%

Higher than 66% of US stocks

Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−1.3%

Higher than 39% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Apnimed, Inc. has a market value of $669.8M and an enterprise value of $368.1M.

  • Shares outstanding: 39.8M.

  • Trailing P/E: 1.2×.

  • Apnimed, Inc. employs 112 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

APMD and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
APMDApnimed, Inc.$669.8M4
NVCTNuvectis Pharma, Inc.$666.8M50
OABIOmniAb, Inc.$677.5M99
LXRXLexicon Pharmaceuticals, Inc.$680.8M69
ATTOAttovia Therapeutics, Inc.$688.2M4
PRMEPrime Medicine, Inc.$643.9M63
SLDBSolid Biosciences, Inc.$697.6M43

Take a look at APMD’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Apnimed, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about APMD

What is the APMD stock price forecast for 2026-2027?

The median 12-month analyst price target for Apnimed, Inc. is $50, with estimates ranging from $40 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is APMD stock a buy right now?

Of the 4 analysts covering Apnimed, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Apnimed, Inc. 4 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank APMD?

As at 21 Nov 2026, Apnimed, Inc. ranks 4 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (57 of 100).

Will APMD stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts is $50, and Ticker Nerd's factor model ranks Apnimed, Inc. 4 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the APMD stock forecast for 2030?

No analyst covering Apnimed, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for APMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $60 over the next 12 months.

What does Apnimed, Inc. do?

Apnimed, Inc. is a clinical-stage pharmaceutical company focused on developing oral therapies for sleep-related breathing diseases, with an emphasis on obstructive sleep apnea. Its lead product candidate, AD109, is an investigational once-daily oral therapy designed to target the underlying neuromuscular dysfunction associated with OSA.

Company

About Apnimed, Inc.

Apnimed, Inc. is a clinical-stage pharmaceutical company focused on developing oral therapies for sleep-related breathing diseases, with an emphasis on obstructive sleep apnea. Its lead product candidate, AD109, is an investigational once-daily oral therapy designed to target the underlying neuromuscular dysfunction associated with OSA. The company’s work centers on advancing medicines that may address mild, moderate, and severe forms of sleep apnea through a simplified pill-based approach. Based in Cambridge, Massachusetts, and founded in 2017, Apnimed operates within the biotechnology and sleep medicine markets, where it contributes to the development of new treatment options for patients with chronic breathing disorders during sleep.

CEO Mr. Kevin Robert Lind · 112 employees · United States · https://apnimed.com